http://www.bioportfolio.com/cgi-bin/acatalog/The_Global_Rheu matoid_Arthritis_Market_Forecasts_to_2012.html Interesting but alas, old since they have 2007 as the future.
What is exciting is that the older TNF's are losing their patent protection.
Which means Enbrel, Humira and Remicade will be cheaper. Yeah.
Bee
Copyright ArthritisInsight.com